Sermorelin occupies a genuinely unusual position among the peptides I've covered in this series: it's the only one that was ever actually FDA-approved. I think that fact gets used in marketing more than it gets explained, so I want to walk through what that approval actually covered, why it went away, and what current evidence for its popular adult uses actually looks like — applying the same evidence framework I've used throughout this pillar.
What sermorelin actually is
Sermorelin is a synthetic version of the first 29 amino acids of growth hormone-releasing hormone (GHRH) — the shortest fragment that retains full activity of the natural hormone. It doesn't supply growth hormone directly. Instead, it signals the pituitary gland to produce and release its own GH, in the body's natural pulsatile pattern. This matters mechanistically: because it works through the body's own feedback system, GH release still stays subject to the natural brake of somatostatin, which is part of why it's generally considered to carry a different, more moderate risk profile than direct growth hormone administration.
The regulatory history, precisely
In 1997, the FDA approved sermorelin under the brand name Geref — but I want to be exact about what that approval actually covered, because it's narrower than most people assume. It was approved specifically as a diagnostic tool, to help evaluate suspected growth hormone deficiency in children. It was not approved as an ongoing therapy for anything, in children or adults.
The manufacturer voluntarily withdrew Geref from the market in 2008, and the FDA's own records confirm this was a commercial decision, not a safety issue — recombinant GH products had come to dominate the growth-hormone-deficiency treatment landscape, and the market for a diagnostic GHRH product had shrunk to the point where maintaining it commercially no longer made sense.
So the honest regulatory position today is this: sermorelin has real prior FDA approval history, which does give compounding pharmacies stronger legal footing to produce it than peptides that were never approved for anything. But that approval covered a single pediatric diagnostic use that no longer exists as a marketed product, and every current adult use — sleep, body composition, energy, recovery — is off-label prescribing through standard compounding pharmacy law, not an FDA-sanctioned indication.
The evidence, tier by tier, for what it's actually used for today
Tier 1 (RCT human data) for the mechanism itself: reasonably solid. That sermorelin reliably stimulates pulsatile GH release, confirmable through IGF-1 lab monitoring, is well-established pharmacology, not a contested claim.
Tier 1 human data for the specific adult wellness claims it's marketed for: does not exist. I want to be direct about this, because it's the gap most likely to get glossed over. Sleep quality, body composition changes, cognitive effects, energy — the claims most commonly made for sermorelin in adult wellness and anti-aging contexts — have not been tested in sermorelin-specific human clinical trials for these outcomes. What exists instead is mechanistic plausibility (GH does influence these systems) and a body of evidence drawn from actual growth hormone replacement trials in adults with diagnosed GH deficiency — a genuinely different population using a different drug (direct GH, not sermorelin) for a different indication than most people using sermorelin today.
Tier 3/4 for the current popular use case: this is where most sermorelin use actually sits. Reports of improved sleep, skin, or cognition during sermorelin therapy are, by the most careful sources I could find, largely anecdotal. That doesn't mean they're false — mechanistic plausibility is real here — but it means the evidence base for "GH optimization" wellness use is meaningfully thinner than the peptide's approval history might suggest to someone encountering it for the first time.
Why this connects to tesamorelin, which I've already covered
This is worth naming directly. Tesamorelin, which I covered earlier in relation to adipose signaling, is also a GHRH analog — and it's currently FDA-approved, with real randomized trial evidence, specifically for reducing visceral fat in a defined patient population. Sermorelin and tesamorelin share a mechanism family, but they occupy very different evidence positions today: one has active, current approval backed by modern trial data; the other has a historical approval for an unrelated, narrow pediatric use and relies on off-label extrapolation for its current popular applications. Conflating the two — treating sermorelin's history as though it confers tesamorelin's current evidence base — is exactly the kind of category error this evidence framework is meant to prevent.
What I'd want you to take from this
Sermorelin's mechanism is genuinely well-understood, and its prior FDA history gives it firmer legal footing than most peptides discussed in wellness spaces. But "was once FDA-approved" and "is proven for what it's being used for today" are two different claims, and the gap between them is real here. If sermorelin is genuinely relevant to your situation — most clearly for actual, diagnosed growth hormone deficiency rather than general wellness optimization — that's a conversation worth having directly with a provider who can weigh your specific case against what the evidence currently does and doesn't show.
Curious whether sermorelin might be relevant to your own hormonal health picture?
No spam. Occasional new posts and updates from The Center for Metabolic Health.
Medical disclaimer: This content is provided for general educational and informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any condition, and it does not create a physician-patient relationship. Every patient's medical history, health status, and treatment needs are different. Always consult your own physician or qualified healthcare provider before starting, stopping, or changing any medication or treatment, and before making any decisions based on information found here. If you are experiencing a medical emergency, call 911 or go to your nearest emergency room.